论文部分内容阅读
本文研究了交替使用针对淋系和髓系的双重化学调节剂Ara-C、Hu及VP16对复发及难治性ALL的治疗作用。 病人及方法:复发性ALL6例,年龄6～12岁,男4人,女2人,标危4人,高危2人,L1 4人,L2 2人。除1例从未CR外,其他5例均在CR后21～32个月复发。由于复发或难治性ALL时常在同一细胞上表达有早期淋系和髓系的抗原,因此作者应用双重化学调节的概念设计了由Ara-C、Hu和VP16组成的营救方案以期达到更好的治疗效果。该方案由两个周期
In this paper, we investigated the therapeutic effects of alternating use of dual chemical regulators Ara-C, Hu and VP16 targeting lymphoid and myeloid lines on relapsed and refractory ALL. Patients and Methods: 6 cases of recurrent ALL, aged 6 to 12 years old, 4 males and 2 females, the standard risk of 4 people, high risk of 2 people, L1 4 people, L2 2 people. All but one case had never CR, the other 5 cases recurred 21 ~ 32 months after CR. Because relapsed or refractory ALL often express early lymphoid and myeloid antigens on the same cell, the authors designed a rescue protocol consisting of Ara-C, Hu and VP16 using the concept of dual chemical regulation in order to achieve better treatment effect. The program consists of two cycles